articleThe LancetJul 14, 2017Closed access

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

University of Iowa · University of Pennsylvania · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,866
total citations
FWCI
60.66
Percentile
100%
References
45
Citations per year

Authors

36

Topics & keywords

Keywords
  • Medicine
  • RPE65
  • Visual acuity
  • Clinical endpoint
  • Randomized controlled trial
  • Clinical trial
  • Ophthalmology
  • Pediatrics
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding